INTRODUCTION
combination with hyperthermic intraperitoneal The prognosis of many patients with gastrointestinal chemotherapy has improved the prognosis of some malignancies is poor due to peritoneal carcinomatosis, defined groups of patients, in particular those with the most frequent site of tumour recurrence. 1 The appendiceal carcinoma. 4 natural history of peritoneal carcinomatosis from nonDue to the physiological circulation of peritoneal fluid gynaecological malignancies is dismal, with a median and tumour cell entrapment, peritoneal carcinomatosis survival time of 3 to 9 months. 2, 3 No effective treatment tends to occur in certain areas of the peritoneal surface, option is available for patients with extensive peritoneal preferentially on the undersurface of the diaphragm, the carcinomatosis.
liver surface, the lesser omentum, the bursa omentalis, Over the last decade the concept of complete surgical the mesocolon and in the pelvis. 5 All peritoneal nodules in these areas should be removed during resection. Based on the typical distribution of the nodules, resection types were systematized into six so-called ''peritonectomy exchanger in the circuit. All information was recorded in a peritoneal carcinomatosis database, including hyperthermic chemotherapy is performed in order to epidemiological, surgical, pathological and survival data. destroy free tumour cells or small residual nodules (up Survival rates were calculated by the Kaplan-Meier to 2-3 mm). Hyperthermia has an independent cytotoxic method and statistical significance was assessed with the effect and also increases the antiproliferative activity of log-rank test using the Statistical Package for the Social chemotherapy.
7,8
Sciences software (SPSS 8.0, Chicago, Illinois). This treatment was pioneered by Sugarbaker in Probabilities of less than 0.05 were accepted as significant. Washington (USA) and the number of patients treated by his group has now risen to over 400. 9 Adequate
RESULTS
patient selection is important for the success of this treatment concept. 10 The best results are obtained in
Surgical therapy
asymptomatic patients with small-volume peritonealIn all patients cytoreductive surgery was possible using surface malignancies in whom complete cytoreduction the peritonectomy procedures (median 4 procedures is possible. Low-grade histology and the absence of per patient, range 2-6) ( Table 3 ). In some cases extended distant metastases is obligatory. 4, 11 surgery (separate from the peritonectomy procedures) In 1995 we started to treat patients with peritoneal was undertaken: partial pancreatectomy (n=5), carcinomatosis of appendiceal origin by multimodality segmental resection of small intestine (n=4), treatment, and the aim of this study was to analyse the subsegmental liver resection (n=3), partial diaphragmatic results in our own series. resection (n=9) and ovariectomy (n=2). The median operating time was 9 hours (range 4-12). Six units of blood per patient were administered during surgery
PATIENTS AND METHODS
(range [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . The median number of gastrointestinal From July 1995 to January 2000, 17 patients with anastomoses performed was one (range 0-4). peritoneal carcinomatosis from an appendiceal carcinoma Macroscopically complete cytoreduction was achieved were operated upon (Table 1) in the Klinik für Viszeralin 12 patients (70%). In five patients small nodules up to und Transplantationschirurgie of the Medical School of 2-3 mm, mainly penetrating the small intestine, were not Hannover. Another seven patients who were referred resectable so that only incomplete cytoreduction was to our department were excluded from this protocol possible (n=5, 30%). because they had distant metastases or large tumour masses in the small bowel mesentery.
Postoperative morbidity and mortality
All patients had undergone previous surgery and one of them had been treated preoperatively with systemic
Complications occurred in 11 patients (65%) postoperatively. ''Non-surgical'' complications occurred chemotherapy ( Table 2 ). The median time interval The overall mean survival time was 39±4 months and Single-institution data for more than 400 patients with this disease have been reported and the results are encouraging, with a 5-year survival rate of 74%. 9 more often than ''surgical'' and included morbidity due to the cisplatin chemotherapy ( Table 4) . The Based on these data and other published reports, 15 we have treated patients with peritoneal carcinomatosis characteristics of the patients who experienced grade II or III renal toxicity are described in Table 5 . In five cases in a different fashion since 1995. We changed our approach by trying to achieve a macroscopically complete further surgery was required (30%), in all other cases complications were treated medically. resection of peritoneal nodules, then administering open intraperitoneal hyperthermic chemotherapy. The hospital mortality rate was 11% (n=2). One volume are good candidates for this aggressive treatment. However, massive tumour involvement of the smallbowel mesentery, an inability to achieve complete cytoreduction and the presence of haematogenous metastases are contraindications to multimodality treatment.
11 As this selection is usually very difficult, attempts were made to systematize this procedure, for instance with the introduction of the Peritoneal Cancer Index.
12 This also made possible the comparison of results reported by different groups.
In our series we re-operated upon these patients with the aim of achieving macroscopically complete cisplatin, as reported by others, 16 although other agents have also been used for intraperitoneal therapy (e.g. TNF).
15
Chemotherapy was combined with hyperthermia in order to increase the cytotoxic effect. 17 The temperatures we achieved (41°to 42°C) are similar to published data. 7, 8, 14 We preferred the open technique because by this method a homogeneous distribution of chemotherapy into the abdominal cavity can be assured. 12 We have previously demonstrated by peritoneal scintigraphy that some areas of the peritoneal surface are not reached by chemotherapy during closed intraperitoneal therapy. 18 As others have reported, we found an increased postoperative morbidity and mortality after extended Most of the complications were either haematological with grade III toxicity also developed surgical complications, with bowel perforation and peritonitis, so that the impaired renal function had multiple causes. More experienced centres have shown that not every
The use of protective agents such as Amofostine can patient with peritoneal carcinomatosis can be treated in reduce the renal toxicity of cisplatin. 19 However, this way and that many patients with advanced disease experienced centres have found that morbidity correlates have been treated with minimal benefit. 10 Patients who particularly with the extent of resection 20 and not so are selected for the treatment should be in a good much with increased intra-abdominal temperature. It is general condition so that they will tolerate major surgery.
likely that the results are influenced by the ''learningcurve'' of this complex treatment strategy. 
